AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Level 3 Rollforward — Additions by Quarter
Level 3 Rollforward — Additions ($M) ($M)
AbbVie Level 3 Rollforward — Additions: $0M in Q2 2026.
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
20 quarters
Since Q3 2016
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Level 3 Rollforward — Additions ($M), quarterly Q3 2016–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-additions
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.